Astrazeneca Shs Sponsored American Deposit Receipt Repr 1 Sh $69.01

up +1.23


24/4/2014 06:40 PM  |  NYSE : AZN  
Industries : Drugs / Drug Manufacturers - Major
Get Trend Analysis Icon Get AZN Trend Analysis - it has outperformed the S&P 500 by 15%

Partner Headlines

  1. Drugmakers' Q1 was anemic

    IBD
  2. Market Wrap For April 24: Apple's Smashing Earnings Overshadowed By Ukraine ...

    Benzinga
  3. Stock Futures Point Due North; Apple, Facebook Lead Tech Surge

    IBD
  4. Drugmakers Prod European Stocks To Post-Easter Rally

    IBD
  5. Valeant's Bid For Allergan Boosts Ethical Drug Stocks

    IBD
  6. Novartis, Glaxo Swap Units; Valeant Bids For Allergan

    IBD
  7. Drug ETFs Surge On M&A Activity (AGN, VRX, IHE, XPH, PPH, AZN)

    Benzinga
  8. Astrazeneca Down 3% Despite Citigroup Upgrade

    Benzinga
  9. Valeant, Ackman Eye Allergan

    IBD
  10. Pfizer may make cancer play

    IBD
  11. Market Wrap For April 21: S&P 500 Extends Winning Streak To Five Days, ...

    Benzinga
  12. Mid-Day Market Update: AMD Surges After Upbeat Results; Acacia Research ...

    Benzinga
  13. Pfizer, AstraZeneca Rise On Report Of Merger Talks

    IBD
  14. Benzinga's Volume Movers

    Benzinga
  15. Mid-Morning Market Update: Markets Rise; Halliburton Posts Q1 Profit

    Benzinga
  16. Morning Market Movers

    Benzinga
  17. Rumor: Pfizer Planning $100 Billion Bid For AstraZeneca

    Benzinga
  18. Benzinga's Top #PreMarket Gainers

    Benzinga
  19. Stock Futures Drift Higher After Best Week since July

    FoxBusiness
  20. Wall Street Edges Higher in Quiet Trading

    FoxBusiness
  21. Benzinga's Weekend M&A Chatter

    Benzinga
  22. Sunday Times Reports Pfizer Considering $100B Offer for AstraZeneca

    Benzinga
  23. Myriad, Tata Motors Among RS Leaders In Correction

    IBD
  24. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With The Highest ...

    Benzinga
  25. Abbott Capturing Incremental Market Share

    GuruFocus
  26. Abbvie's Humira Continues to be a Powerful Catalyst for Growth

    GuruFocus
  27. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  28. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  29. AstraZeneca hurt by generics

    IBD
  30. AstraZeneca Q4 Mixed, But Alzheimer's Drug Advances

    IBD
  31. Bristol-Myers 4Q Earnings Beat the Street

    FoxBusiness
  32. Market Wrap For January 22: Earnings Season Continues To Come In Mixed

    Benzinga
  33. Bristol-Myers: Don't Let This One Get Away

    GuruFocus
  34. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think It Is

    GuruFocus
  35. Market Wrap For January 14: Markets Rebound On Earnings Season Kickoff

    Benzinga
  36. Stocks Hitting 52-Week Highs

    Benzinga
  37. Jazz, Valeant Join Drug Makers' Q4 Merger Rush

    IBD
  38. ObamaCare = Drug Maker Assistance Act

    YCharts
  39. Merck’s Bad-Mouthing Of Generic: $21 Million Fine

    YCharts
  40. Benzinga's Top Downgrades

    Benzinga
  41. AstraZeneca in $4 bil-plus buy

    IBD
  42. Bristol-Myers' Diabetes Sale Sharpens Biopharma Focus

    IBD
  43. Market Wrap For December 18: Markets Flat During Day One Post Fed Taper

    Benzinga
  44. Bristol-Myers Dumping Disaster Onto AstraZeneca?

    YCharts
  45. AstraZeneca Buys Out Bristol-Myers' Diabetes Business

    IBD
  46. AstraZeneca to Buy Bristol's Stake in Joint Venture

    FoxBusiness
  47. Cubist drug passes 2nd test

    IBD
  48. Suppose Medicare Negotiated Like This?

    YCharts
  49. Pfizer’s Great Hope Xeljanz: More Bad News

    YCharts
  50. Cubist Antibiotic Passes Second Test; FDA Filing Next

    IBD
Trading Center